Evidence map›Paper›PMID 36250791›Full record

ArticleG3 (Bethesda, Md.)2022

Assessing single-locus CRISPR/Cas9-based gene drive variants in the mosquito Aedes aegypti via single-generation crosses and modeling.

William Reid, Adeline E Williams, Irma Sanchez-Vargas, Jingyi Lin, Rucsanda Juncu, Ken E Olson, Alexander W E Franz

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cytoskeleton-associated gelsolin responds to the midgut distention process in saline meal-fed Aedes aegypti and affects arbovirus dissemination from the midgut.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Quantifying Fitness Costs in Transgenic Aedes aegypti Mosquitoes.Journal of visualized experiments : JoVE · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

William ReidDepartment of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.
Adeline E WilliamsDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0002-8433-0060
Irma Sanchez-VargasDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Jingyi LinDepartment of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.
Rucsanda JuncuDepartment of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.
Ken E OlsonDepartment of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Alexander W E FranzDepartment of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.ORCID 0000-0002-3243-8408

Funding

Engineering resistance to Zika virus in Aedes aegypti for Cas9 driven population modificationR01AI130085 · NIAID · COLORADO STATE UNIVERSITY · PI OLSON, KENNETH E · 2018 to 2021
$2.7M
Optimization of low-threshold Cas9-based gene drive systems to introduce Zika virus resistance in Aedes aegyptiR56AI167980 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI FRANZ, ALEXANDER W E · 2022 to 2022
$537k
NIAID NIH HHS R01 AI130085NIAID NIH HHS R56 AI167980
6 · The paper itself

Abstract

The yellow fever mosquito Aedes aegypti is a major vector of arthropod-borne viruses, including dengue, chikungunya, and Zika viruses. A novel approach to mitigate arboviral infections is to generate mosquitoes refractory to infection by overexpressing antiviral effector molecules. Such an approach requires a mechanism to spread these antiviral effectors through a population, for example, by using CRISPR/Cas9-based gene drive systems. Critical to the design of a single-locus autonomous gene drive is that the selected genomic locus is amenable to both gene drive and appropriate expression of the antiviral effector. In our study, we used reverse engineering to target 2 intergenic genomic loci, which had previously shown to be highly permissive for antiviral effector gene expression, and we further investigated the use of 3 promoters (nanos, β2-tubulin, or zpg) for Cas9 expression. We then quantified the accrual of insertions or deletions (indels) after single-generation crossings, measured maternal effects, and assessed fitness costs associated with various transgenic lines to model the rate of gene drive fixation. Overall, MGDrivE modeling suggested that when an autonomous gene drive is placed into an intergenic locus, the gene drive system will eventually be blocked by the accrual of gene drive blocking resistance alleles and ultimately be lost in the population. Moreover, while genomic locus and promoter selection were critically important for the initial establishment of the autonomous gene drive, it was the fitness of the gene drive line that most strongly influenced the persistence of the gene drive in the simulated population. As such, we propose that when autonomous CRISPR/Cas9-based gene drive systems are anchored in an intergenic locus, they temporarily result in a strong population replacement effect, but as gene drive-blocking indels accrue, the gene drive becomes exhausted due to the fixation of CRISPR resistance alleles.

Indexed as

AedesGene Drive TechnologyZika VirusZika Virus InfectionAnimalsCRISPR-Cas SystemsMosquito VectorsarbovirusCRISPRgene drive-blocking indelsgenomic position effectpopulation replacement

Identifiers

PMID36250791
PMCPMC9713460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.